Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel de la Torre

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Cardiovascular and Interventional Radiology|June 20, 2020
Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers YetManuel de la Torre-Aláez, Bruno Sangro
Liver International : Official Journal of the International Association for the Study of the Liver|May 22, 2024
The 'BCLC upon progression' classification: After repeated validation, it is time to incorporate it in trial designManuel de la Torre-Aláez, Maria Reig
European Journal of Case Reports in Internal Medicine|February 5, 2020
Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case ReportManuel de la Torre-Aláez, Mercedes Iñarrairaegui
European Urology|April 25, 2006
Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancerAmir Sherif, Ulrike Garske, Manuel de la Torre, et al.
Revista Espanola De Enfermedades Digestivas|June 15, 2022
Immunotherapy in hepatocellular carcinomaManuel de la Torre, Paloma Sangro, Delia D Avola, et al.
Journal of Hepatology|November 18, 2021
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinomaDelia D'Avola, Alessandro Granito, Manuel de la Torre-Aláez, et al.
Expert Opinion on Biological Therapy|August 20, 2025
Tremelimumab for the treatment of hepatocellular carcinomaMiguel Sogbe, Paloma Sangro, Manuel de la Torre-Aláez, et al.
Journal of Physiology and Biochemistry|March 28, 2023
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatmentPaloma Sangro, Manuel de la Torre Aláez, Bruno Sangro, et al.
BJU International|April 21, 2005
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastasesTruls Gårdmark, Kenneth Wester, Manuel De la Torre, et al.
Acta Oncologica (Stockholm, Sweden)|August 28, 2002
HER-2--a possible target for therapy of metastatic urinary bladder carcinomaKenneth Wester, Anna Sjöström, Manuel de la Torre, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Cardiovascular and Interventional Radiology|June 20, 2020
Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers YetManuel de la Torre-Aláez, Bruno Sangro
Liver International : Official Journal of the International Association for the Study of the Liver|May 22, 2024
The 'BCLC upon progression' classification: After repeated validation, it is time to incorporate it in trial designManuel de la Torre-Aláez, Maria Reig
European Journal of Case Reports in Internal Medicine|February 5, 2020
Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case ReportManuel de la Torre-Aláez, Mercedes Iñarrairaegui
European Urology|April 25, 2006
Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancerAmir Sherif, Ulrike Garske, Manuel de la Torre, et al.
Revista Espanola De Enfermedades Digestivas|June 15, 2022
Immunotherapy in hepatocellular carcinomaManuel de la Torre, Paloma Sangro, Delia D Avola, et al.
Journal of Hepatology|November 18, 2021
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinomaDelia D'Avola, Alessandro Granito, Manuel de la Torre-Aláez, et al.
Expert Opinion on Biological Therapy|August 20, 2025
Tremelimumab for the treatment of hepatocellular carcinomaMiguel Sogbe, Paloma Sangro, Manuel de la Torre-Aláez, et al.
Journal of Physiology and Biochemistry|March 28, 2023
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatmentPaloma Sangro, Manuel de la Torre Aláez, Bruno Sangro, et al.
BJU International|April 21, 2005
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastasesTruls Gårdmark, Kenneth Wester, Manuel De la Torre, et al.
Acta Oncologica (Stockholm, Sweden)|August 28, 2002
HER-2--a possible target for therapy of metastatic urinary bladder carcinomaKenneth Wester, Anna Sjöström, Manuel de la Torre, et al.
Pageof 7